Trial of ND-003 for advanced solid cancers
Part of Cancer clinical trials.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has continued to grow despite standard treatments, or no standard treatment exists.
- You have a tumor that can be measured on imaging (like a CT scan).
- You are 18 years or older and able to care for yourself (ECOG 0–2).
- Your heart, liver, kidneys, and bone marrow are working well enough based on blood tests.
- You do not have uncontrolled infections, heart conditions, or other serious health problems that would make the trial unsafe.
- You have not had chemotherapy or other cancer treatments within 3 to 4 weeks before starting the study (some exceptions apply).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.